New Jersey’s PTC Therapeutics has made a double senior appointment.
Matthew Klein has been promoted to Chief Development Officer and Eric Pauwels to Chief Business Officer.
Dr. Klein will be responsible for the development of our clinical stage programs.
As the Chief Business Officer, Mr. Pauwels will be responsible for our customer facing activities with health care providers, patients and payers ensuring that our therapies are available and accessible to rare disease patients and their families worldwide.
“In their new roles, they will continue to advance our development pipeline, fuel our company’s growth and deliver on our mission to develop and provide transformative therapies for patients living with rare disorders,” said CEO Stuart Peltz.
Dr Klein joined PTC last year as Global Head of Gene & Mitochondrial Therapies after serving as CEO and Chief Medical Officer of BioElectron Technology Corporation, certain assets of which were acquired by PTC in 2019.
Prior to leading BioElectron, he was the Auth-Washington Research Chair of Restorative Burn Surgery at the University of Washington.
Mr Pauwels joined PTC in 2015 as Senior Vice President and General Manager of the Americas, overseeing commercial strategy and market access.
Prior, he served as the Chief Commercial Officer at NPS Pharmaceuticals and President of NPS Pharma International.
Previously, he served as Senior Vice President of Global Commercial Operations at Shire Human Genetic Therapies.